Another observational study was performed by Stapleton and collaborators to assess the effects of ETI therapy on sinonasal symptoms of 34 adults with CF (average age of 27 years, 67% homozygous for F508del-CFTR) [67]. The gene discussed is CFTR; the disease is cystic fibrosis.